As the opioid crisis dawned in the U.S., continuing educational material that doctors are required to review may have contributed to the burgeoning problem, according to a newly published study.
How so? The study compared a continuing medical education module, or course, that was funded by a drug maker that sold a fentanyl lollipop and lozenge with practice guidelines issued by a medical society. The scope of the two publications was not completely identical, but both focused on the use of opioids in treating non-cancer pain. And the study found the industry-funded course contained a “subtle bias.”
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
